scholarly journals Identifying Heart Failure from Electronic Health Records: A Systematic Evidence Review

Author(s):  
Rebecca T. Levinson ◽  
Jennifer R. Malinowski ◽  
Suzette J. Bielinski ◽  
Luke V. Rasmussen ◽  
Quinn S. Wells ◽  
...  

ABSTRACTBackgroundHeart failure (HF) is a complex syndrome associated with significant morbidity and healthcare costs. Electronic health records (EHRs) are widely used to identify patients with HF and other phenotypes. Despite widespread use of EHRs for phenotype algorithm development, it is unclear if the characteristics of identified populations mirror those of clinically observed patients and reflect the known spectrum of HF phenotypes.MethodsWe performed a subanalysis within a larger systematic evidence review to assess the different methods used for HF algorithm development and their application to research and clinical care. We queried PubMed for articles published up to November 2020. Out of 318 studies screened, 25 articles were included for primary analysis and 15 studies using only International Classification of Diseases (ICD) codes were evaluated for secondary analysis. Results are reported descriptively.ResultsHF algorithms were most often developed at academic medical centers and the V.A. One health system was responsible for 8 of 10 HF algorithm studies. HF and congestive HF were the most frequent phenotypes observed and less frequently, specific HF subtypes and acute HF. Diagnoses were the most common data type used to identify HF patients and echocardiography was the second most frequent. The majority of studies used rule-based methods to develop their algorithm. Few studies used regression or machine learning methods to identify HF patients. Validation of algorithms varied considerably: only 52.9% of HF and 44.4% of HF subtype algorithms were validated, but 75% of acute HF algorithms were. Demographics of any study population were reported in 68% of algorithm studies and 53% of ICD-only studies. Fewer than half reported demographics of their HF algorithm-identified population. Of those reporting, most identified majority male (>50%) populations, including both algorithms for HF with preserved ejection fraction.ConclusionThere is significant heterogeneity in phenotyping methodologies used to develop HF algorithms using EHRs. Validation of algorithms is inconsistent but largely relies on manual review of patient records. The concentration of algorithm development at one or two sites may reduce potential generalizability of these algorithms to identify HF patients at non-academic medical centers and in populations from underrepresented regions. Differences between the reported demographics of algorithm-identified HF populations those expected based on HF epidemiology suggest that current algorithms do not reflect the full spectrum of HF patient populations.

Author(s):  
Victor M. Castro ◽  
Rachel A. Ross ◽  
Sean M. McBride ◽  
Roy H. Perlis

AbstractImportanceAbsent a vaccine or any established treatments for the novel and highly infectious coronavirus-19 (COVID-19), rapid efforts to identify potential therapeutics are required.ObjectiveTo identify commonly-prescribed medications that may be associated with lesser risk of morbidity with COVID-19 across 5 Eastern Massachusetts hospitals.DesignIn silico cohort using electronic health records between 7/1/2019 and 4/07/2020. Setting: Outpatient, emergency department and inpatient settings from 2 academic medical centers and 3 community hospitals.ParticipantsAll individuals presenting to a clinical site and undergoing COVID-19 testing.Main Outcome or MeasureInpatient hospitalization; documented requirement for mechanical ventilation.ResultsAmong 12,818 individuals with COVID-19 testing results available, 2271 (17.7%) were test-positive, and 707/2271 (31.1%) were hospitalized in one of 5 hospitals. Based on a comparison of ranked electronic prescribing frequencies, medications enriched among test-positive individuals not requiring hospitalization included ibuprofen, valacyclovir, and naproxen. Among individuals who were hospitalized, mechanical ventilation was documented in 213 (30.1%); ibuprofen and naproxen were also more commonly prescribed among individuals not requiring ventilation.Conclusions and RelevanceThese preliminary findings suggest that electronic health records may be applied to identify medications associated with lower risk of morbidity with COVID-19, but larger cohorts will be required to address confounding by indication. Larger scale efforts at repositioning may help to identify FDA-approved medications meriting study for prevention of COVID-19 morbidity and mortality.Fundingnone.Key PointsQuestionCan electronic health records identify medications that may be associated with diminished risk of COVID-19 morbidity?FindingsThis cohort study across 5 hospitals identified medications enriched among individuals who did not require hospitalization for COVID-19 despite a positive test.MeaningWhile preliminary and subject to confounding, our results suggest that electronic health records may complement efforts to identify novel therapeutics for COVID-19 by identifying FDA-approved compounds with potential benefit in reducing COVID-19-associated morbidity.


2021 ◽  
Vol 26 (5) ◽  
pp. 4502
Author(s):  
S. R. Gilyarevsky ◽  
D. V. Gavrilov ◽  
A. V. Gusev

The article presents the first experience of analyzing the treatment quality of hospitalized patients with heart failure based on electronic health records (EHR). We analyzed EHR of patients hospitalized in three large hospitals in Kirov. The results of the analysis indicated insufficient detailed information in the EHR, which complicates analyzing the accuracy of diagnosis and therapy quality. In particular, attention is drawn to the disproportionate number of patients with heart failure with reduced and preserved ejection fractionю This, apparently, is due to the low prevalence of assessing brain natriuretic peptides and conducting Doppler echocardiography. A separate part of the analysis is devoted to assessing the therapy quality in patients with concomitant diabetes. Despite the study limitations, the presented results can be useful for improving the quality of EHR filling for performing further observational clinical trials.


2021 ◽  
Author(s):  
Marika Cusick ◽  
Sumithra Velupillai ◽  
Johnny Downs ◽  
Thomas Campion ◽  
Rina Dutta ◽  
...  

Abstract In the global effort to prevent death by suicide, many academic medical institutions are implementing natural language processing (NLP) approaches to detect suicidality from unstructured clinical text in electronic health records (EHRs), with the hope of targeting timely, preventative interventions to individuals most at risk of suicide. Despite the international need, the development of these NLP approaches in EHRs has been largely local and not shared across healthcare systems. In this study, we developed a process to share NLP approaches that were individually developed at King’s College London (KCL), UK and Weill Cornell Medicine (WCM), US - two academic medical centers based in different countries with vastly different healthcare systems. After a successful technical porting of the NLP approaches, our quantitative evaluation determined that independently developed NLP approaches can detect suicidality at another healthcare organization with a different EHR system, clinical documentation processes, and culture, yet do not achieve the same level of success as at the institution where the NLP algorithm was developed (KCL approach: F1-score 0.85 vs. 0.68, WCM approach: F1-score 0.87 vs. 0.72). Shared use of these NLP approaches is a critical step forward towards improving data-driven algorithms for early suicide risk identification and timely prevention.


2019 ◽  
Vol 21 (10) ◽  
pp. 1197-1206 ◽  
Author(s):  
Alicia Uijl ◽  
Stefan Koudstaal ◽  
Kenan Direk ◽  
Spiros Denaxas ◽  
Rolf H. H. Groenwold ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document